Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Novo Nordisk A/S NVO New York Stock Exchange

New York Stock Exchange • Healthcare • Drug Manufacturers - General • DK • USD

SharesGrow Score
81/100
5/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$47.00
+19.5%

Novo Nordisk A/S (NVO) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $39.32. It has a SharesGrow Score of 81/100, indicating a strong investment profile with 5 out of 7 criteria passed.

Analyst consensus target is NVO = $47 (+19.5% upside).

Financials: revenue is $297.2B, +19.5%/yr average growth. Net income is $98.5B, growing at +23%/yr. Net profit margin is 33.1% (strong). Gross margin is 80.3% (-3.6 pp trend).

Balance sheet: total debt is $131.0B against $194.0B equity (Debt-to-Equity (D/E) ratio 0.67, moderate). Current ratio is 0.8 (tight liquidity). Debt-to-assets is 24.1%. Total assets: $542.9B.

Analyst outlook: 23 / 39 analysts rate NVO as buy (59%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 86/100 (Pass), Growth 90/100 (Pass), Past 100/100 (Pass), Health 50/100 (Partial), Moat 85/100 (Pass), Future 58/100 (Partial), Income 100/100 (Pass).

$47.00
▲ 19.53% Upside
Average Price Target
Based on 39 Wall Street analysts offering 12-month price targets for Novo Nordisk A/S, the average price target is $47.00, with a high forecast of $54.00, and a low forecast of $42.00.
Highest Price Target
$54.00
Average Price Target
$47.00
Lowest Price Target
$42.00

NVO SharesGrow Score Overview

81/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 86/100
Valuation — P/E, PEG, Forward PEG
GROWTH 90/100
Financials — average growth
PAST 100/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 85/100
Gross margin is + market cap
FUTURE 58/100
Analyst outlook — as buy
INCOME 100/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NVO

✓
VALUE Pass
86/100
NVO trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $47, implying +19.5% from the current price $39. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
90/100
NVO: +19.5%/yr revenue is, +23%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✓
PAST Pass
100/100
NVO: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
50/100
Balance sheet NVO: Debt-to-Equity (D/E) ratio 0.67 (moderate), Current ratio is 0.8 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
85/100
NVO: Gross margin is 80.3% (-3.6 pp trend), $175B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 85/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
58/100
Analyst outlook: 23 / 39 analysts rate NVO as buy (59%). Analyst consensus target is $47 (+19.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✓
INCOME Pass
100/100
NVO: Net profit margin is 33.1%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range35.12-81.44
Volume19.61M
Avg Volume (30D)23.29M
Market Cap$174.74B
Beta (1Y)0.27
Dividend Yield$1.3274
Share Statistics
EPS (TTM)23.06
Shares Outstanding$4.45B
IPO Date1981-04-30
Employees77,406
CEOMaziar Mike Doustdar
Financial Highlights & Ratios
Revenue (TTM)$297.2B
Gross Profit$238.77B
EBITDA$143.94B
Net Income$98.5B
Operating Income$129.83B
Total Cash$26.96B
Total Debt$130.96B
Net Debt$104.49B
Total Assets$542.9B
Price / Earnings (P/E)1.7
Price / Sales (P/S)0.59
Analyst Forecast
1Y Price Target$45.00
Target High$54.00
Target Low$42.00
Upside+14.4%
Rating ConsensusBuy
Analysts Covering39
Buy 59% Hold 33% Sell 8%
Price Target Summary
Company Info
CountryDK
ExchangeNew York Stock Exchange
CurrencyUSD
ISINUS6701002056

Price Chart

Track all markets on TradingView
NVO
Novo Nordisk A/S ↗  ·  New York Stock Exchange
Healthcare • Drug Manufacturers - General
35.12 52WK RANGE 81.44

People Also View

AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
 NVS
NVS
Novartis AG
$153.38
-0.71%
 TMO
TMO
Thermo Fisher Scientific Inc.
$527.22
+2.53%
 AMGN
AMGN
Amgen Inc.
$350.95
+0.32%
 ABT
ABT
Abbott Laboratories
$101.07
+0.38%
 GILD
GILD
Gilead Sciences, Inc.
$140.45
+1.02%
 PFE
PFE
Pfizer Inc.
$27.13
-0.77%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message